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In the  past  years,  new  generations  of assays  to detect  cardiac  troponin  (cTn),  called  sensitive  or high
sensitivity  troponin  (hs-Tn),  have  been  introduced.  Progressive  improvement  in the  analytical  sensitivity
of  cTn  assays  has  led to a more  rapid  diagnosis  of  acute  myocardial  infarction  (AMI)  and  improved  risk
stratiﬁcation  in patients  with  non  ST-elevation  acute  coronary  syndromes  (NSTE-ACS)  but,  at  the same
time,  has  introduced  the  problem  of a lower  diagnostic  speciﬁcity.  As  a matter  of  fact,  hs-Tn  assays  are
able  to detect  very  small  increases  in  the  biomarker  concentration  and  therefore  result  “positive”  in a
wide range  of  non-ischemic  clinical  conditions,  acute  and chronic,  cardiac  and  extra-cardiac.  The  reduced
speciﬁcity  of hs-Tn  versus  the  previous  generation  cTn  assays  may,  therefore,  lead  to  an  increased  number
of  inappropriate  hospitalizations,  i.e. patients  with  high  cTn  due  to no-ACS  conditions,  and  requires  a  moreAge approach” careful  evaluation,  not  only  on  the  clinical  side,  but  also  on  the information  that hs-Tn  assessment  may
provide.  Several  approaches  to increase  this  speciﬁcity  have  been  used,  but the  most  promising  appear  to
be the  “delta  approach”,  which  tries  to quantify  the  relative  or absolute  change  in cTn  concentration,  and
the “age  approach”,  which  highlights  the need  for  a different  cutoff  with  a better  diagnostic  efﬁciency  in
the  elderly  population,  often  affected  by  other conditions,  different  from  ACS, that  can  cause  an  increased
level  of  cTn.
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ntroduction controlling contraction and relaxation of skeletal and cardiacCardiac troponins (cTn) are regulatory proteins that play a piv-
tal role in the process of interaction between actin and myosin,
∗ Corresponding author at: Istituto di Cardiologia – Policlinico A Gemelli, L.go
emelli, 8, 00168 Roma, Italy. Tel.: +39 0630154187; fax: +39 063055535.
E-mail address: lmbiasucci@virgilio.it (L.M. Biasucci).
914-5087/$ – see front matter © 2013 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2013.04.005muscle. This complex is formed by three different proteins, bound
to the thin ﬁlaments of the muscle: troponin C (cTnC), which binds
calcium; troponin I (cTnI), which inhibits actin–myosin interac-
tions; troponin T (cTnT), which binds the troponin complex to
tropomyosin and facilitates contraction. cTnC is expressed by cells
in both cardiac and skeletal muscle, in contrast cTnI and cTnT are
unique to cardiac muscle, therefore they can be used as speciﬁc
biomarkers for myocardial damage. CTn are released into the blood
vier Ltd. All rights reserved.
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of hs-Tn is the “delta approach” that tries to quantify the mag-
nitude of concentration changes (ı) in cTn values, obtained by
serial measurement and calculated with the following equation:
ı = Cmax − Cbaseline.
Table 1
Causes of cardiac troponin elevation other than ACS.
Damage related to supply/demand imbalance of myocardial ischemia√
Tachy- or bradyarrhythmias√
Aortic dissection and severe aortic valve disease√
Cardiogenic, hypovolemic or septic shock√
Hypertrophic cardiomyopathy√
Severe respiratory failure√
Severe anemia√
Hypertension with or without LVH√
Coronary embolism or vasculitis, e.g. systemic lupus erythematosus,
Kawasaki syndrome√
Coronary spasm√
Coronary endothelial dysfunction without signiﬁcant CAD, e.g. cocaine
abuse
Damage not due to myocardial ischemia√
Cardiac contusion√
Cardiac incisions with surgery√
Radiofrequency or cryoablation therapy√
Pacing or deﬁbrillator shocks√
Rhabdomyolysis with cardiac involvement√
Myocarditis√
Cardiotoxic agents, e.g. anthracyclines, herceptin, carbon monoxide
poisoning
Multifactorial causes of myocardial damage√
Heart failure√
Takotsubo cardiomyopathy√
Severe pulmonary embolism or pulmonary hypertension√
Renal failure√
Severe acute neurological diseases, e.g. stroke, trauma√
Inﬁltrative diseases, e.g. amyloidosis, sarcoidosis06 M.G. Marini et al. / Journal 
tream after myocardial damage, ﬁrst from an “early appearing”
yocyte pool and subsequently from a structural pool [1]. In the
ast 10 years cTn have been identiﬁed as the preferred marker for
cute myocardial infarction (AMI) [2,3] because of their speciﬁcity
or cardiac muscle and sensitivity. The third universal deﬁnition of
I [4], in fact, establishes that the diagnosis of AMI  is based on a ris-
ng and/or falling pattern of cTn serum concentrations with, at least,
ne value above the 99th percentile limit of the reference value dis-
ribution. However, an increased level of cTn is necessary, but not
ufﬁcient, for the diagnosis of AMI, that also requires clinical fea-
ures of myocardial ischemia, indicated by symptoms of ischemia,
lectrocardiographic changes indicative of new ischemia, develop-
ent of pathological Q-waves, or imaging evidence of the new loss
f viable myocardium or new regional wall motion abnormalities
4].
The ﬁrst assays for measurement of cTn appeared in 1991 [5] and
ince then a number of assays have been studied and introduced
n clinical practice. However, the earlier assays were characterized
y an insufﬁcient precision at very low levels of cTn concentra-
ion [expressed as coefﬁcient of variation (CV) > 20% at the 99th
ercentile]. Over time cTn assays have had a signiﬁcant evolution,
eading to more and more sensitive assays, with the aim of allowing
 faster and more reliable diagnosis of AMI  [6–8].
haracteristics and advantages of new high sensitivity
ssays
New generations of assays to detect cTn have been called sensi-
ive or high sensitivity troponin (hs-Tn) and are able to measure cTn
oncentrations approximately 10- to 100-fold lower than conven-
ional assays, allowing a more accurate measurement in particular
t very low concentrations. To be deﬁned as hs-Tn, an assay should
eet two criteria: ﬁrst, the imprecision (CV) at the 99th percentile
alue should be ≤10% (“guideline acceptable”), although assays
ith an imprecision >10% and ≤20% are still “clinically usable” [7].
econd, the assay should be able to measure cTn concentrations
elow the 99th percentile in ≥95% of normal individuals [7].
Only six new hs-Tn assays potentially meet these criteria: ﬁve
s-TnI assays (Abbott ARCHITECT, Beckman Access, Nanosphere
TP, Singulex Erenna, Siemens Vista) and the Roche hs-TnT assay,
hat is commercially available worldwide, except in the USA [7,8].
The introduction of hs-Tn has led to an earlier and more accurate
iagnosis of non ST-elevation acute coronary syndromes (NSTE-
CS), reducing the risk of missing subjects with ACS and improving
he rule out. Previous guidelines for the diagnosis of NSTE-ACS rec-
mmended a second sampling at 6 h to conﬁrm or exclude such
 condition [9], on the contrary, several studies have supported
 reduction of the sampling interval from 6 to 3 h with hs-Tn,
llowing a comparable efﬁcacy and a reduction in unnecessary hos-
italizations and of observation time [8–12]. As a consequence,
urrent European Society of Cardiology guidelines on management
f NSTE-ACS recommend to reduce the minimal time between two
onsecutive blood samples from 6 h to 3 h [13,14].
ore sensitivity, less speciﬁcity: the need to evaluate other
auses of cardiac troponin elevations
Progressive improvement in the analytical sensitivity (SE) of
Tn assays has led to a more rapid diagnosis of AMI  [11,12] and
mproved risk stratiﬁcation in patients with NSTE-ACS [15,16],
ut, at the same time, has introduced the problem of a lower
iagnostic speciﬁcity (SP). It is of remarkable importance to con-
ider that the speciﬁcity of cTn as marker of AMI, caused by
yocardial ischemia, is different from the speciﬁcity as a markeriology 62 (2013) 205–209
of myocardial damage that could be due to other mechanisms.
As a matter of fact, hs-Tn assays are able to detect very small
increases in the biomarker concentration and therefore result “pos-
itive” in a wide range of non-ischemic clinical conditions, acute and
chronic, cardiac and extra-cardiac, such as pericarditis, myocarditis,
Tako-tsubo syndrome, tachyarrhythmias, heart failure, pulmonary
embolism, stroke and sepsis [17,18] (Table 1), thus current guide-
lines recommend that, to make a diagnosis of ACS, it is necessary
to observe a rise and fall in hs-Tn. However, this pattern could also
be found in acute conditions other than ischemic heart disease;
the most common causes of acute elevations of cTn are acute peri-
carditis and myocarditis, tachyarrhythmias and acute pulmonary
embolism (Table 1). Persistent, but without a rise and fall pattern,
elevation of hs-Tn can be found in patients with stable coronary
artery disease (CAD), chronic renal failure, chronic heart failure
(CHF) and severe left ventricular hypertrophy: these conditions
must be differentiated from ACS [19] (Table 1). The need for differ-
entiation of true “thrombotic” MI  from other causes of myocardial
damage has been emphasized, with some excess, also in the recent
“third deﬁnition of MI”  [4].
The reduced speciﬁcity of hs-Tn versus the previous generation
assays may, therefore, lead to an increased number of inappro-
priate hospitalizations, i.e. patients with high cTn due to non-ACS
conditions, and requires a more careful evaluation, not only on the
clinical side, but also of the information that hs-Tn assessment may
provide.
Reducing uncertainty in ACS diagnosis: the “delta approach”
The most frequently used approach for a correct evaluation√
Extreme exertion√
Sepsis
ACS, acute coronary syndrome; LVH, left ventricular hypertrophy; CAD, coronary
artery disease.
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elative ı
Early studies investigated the use of relative ı, that is a ratio
here the ı is expressed relative to a denominator and reported as
 percentage: relative ı = Cmax − Cbaseline/Cbaseline × 100 [20].
The ﬁrst data in the literature concern the use of traditional
Tn assays. In 2007, the US National Academy of Clinical Biochem-
stry (NACB) recommended a ı change in cTn of ≥20% 6–9 h after
resentation, but this indication was based on analytical consider-
tions only in a subset of patients affected by conditions with low
ncreases in baseline concentration of cTn [21].
Apple et al. tested different percentage changes of a second gen-
ration cTnI (≥10, ≥20, ≥30%) and reported that ≥30% change in
TnI should be used in addition to the baseline or follow-up con-
entration, with a SE of 75% and a SP of 90.6%; using a change ≥10%
r ≥20%, diagnostic SE remains 75%, but SP decreased to 81.5% and
6.6% respectively [22].
More recently, other studies have been published regarding hs-
n: in 2010, Giannitsis et al. examined the usefulness of the hs-TnT
 change of a second sample taken within 3–6 h from baseline; the
uthors found that a ROC-optimized ı change of >117% in the ﬁrst
 h and of ≥243% in 6 h yielded a SP of 100% and a SE between 69%
nd 76% [15].
Keller et al. [23] using a hs-TnI assay found that the combi-
ation of the 99th percentile diagnostic cutoff (30 pg/mL) with a
elative ı change in 3 h ≥250%, produced an increase of SP (99.6%)
nd of positive predictive value (PPV) (95.8%), in comparison to the
alue of the 99th percentile cutoff on admission alone (SP 92.1%,
PV 75.1%); this criterion also improved AUC (0.985 vs 0.962).
ollowing this line of research, many other data have been pub-
ished on the role of relative ı: Eggers et al. tested the impact of ı
hange values of ≥20%, ≥50%, and ≥100% and found that the use
f higher relative changes (≥50% or ≥100%) resulted in more fre-
uent false negative results in patients with an index diagnosis of
MI; on the other hand, the use of relative cTnI change of ≥20%
ogether with the Universal Deﬁnition criteria provided an opti-
ized sensitivity [24]. Aldous et al. have published two studies in
mergency Department (ED) populations with chest pain or symp-
oms suggestive of NSTE-ACS; the ﬁrst study conﬁrmed that an
dditional application of a ı ≥ 20% after 2 h for hs-TnT signiﬁcantly
ncreased the speciﬁcity for AMI  (75.6% vs 92.6%), but sensitivity
as markedly reduced (95.1% vs 56.1%) [25]. The second study has
hown that the optimum percent ı for the diagnosis of AMI  depends
n whether the diagnosis is to be ruled in (need for high speciﬁcity),
hich was shown to be a change of >39.7% (SP >90%), or ruled out
need for high sensitivity); in the ﬁrst case the best ı was found
o be 39.7%, in the second a change of only >2.5% (SE > 90%) [26]
Table 2).
bsolute ıMore recently some attention has been focused on a different
pproach regarding cTn ı: Mueller et al. [27] compared dynamic ı
hanges of hs-TnT in patients with a diagnosis of ACS with patients
able 2
elative delta.
ı SE SP
Apple et al. [22] ≥30% 6 h 75% 90.6%
Giannitsis et al. [15] ≥117% 3 h 69–76% 100%
≥243% 6 h
Keller et al. [23] ≥250% 3 h 32.6% 99.6%
Eggers et al. [24] ≥20% 6 h 84%
Aldous et al. [26] ≥10% 2 h 69% 89.7%
Aldous et al. [25] ≥20% 2 h 56.1% 92.6%
E, sensitivity; SP speciﬁcity.iology 62 (2013) 205–209 207
presenting to ED with acute symptoms and cTn increases but
without a diagnosis of ACS. In identiﬁcation of NSTEMI within 3–6 h,
absolute ı changes outperformed relative ı changes (AUC 0.898 vs
0.752, p < 0.0001); compared to a relative ı change of ≥20% (as rec-
ommended by the NACB) [SE 75.2%, negative predictive value (NPV)
89.8%], the ROC-optimized absolute ı change of 9.2 ng/L for the
entire study population, provided a sensitivity of 89.7% and a NPV of
96.5%. Despite the low speciﬁcity (74.8%) and PPV (48.7%), in com-
parison to the ı change ≥20% (SP 58.1%, PPV 32.4%), the absolute
ı demonstrated a signiﬁcant added value (NRI 0.331, p < 0.0001).
In particular, in the ACS population, a ROC-optimized absolute ı
change of 6.9 ng/L led to an improvement in SE 93.3%, NPV 93%, SP
81.9%, and PPV 82.8% if compared with ı change ≥20% (SE 75.2%,
NPV 69.9%, SP 54%, PPV 60.5%). Also the value of the AUC resulted
higher (0.941 for absolute ı vs 0.741 for ı ≥ 20%), with a NRI of 0.499
(p < 0.0001). Reichlin et al. found that the ROC-derived optimal
cutoff value for absolute ı change from baseline to 2 h follow-up
measurement was  7 ng/L (SE 89%, SP, 93%, NPV 98%, PPV 64%), very
close to the previous value [28].
Recently, another study, conducted by the same group, aimed
to create an algorithm for the identiﬁcation of patients with AMI. In
this study, the relative ı change in the ﬁrst hour was 20.8% for AMI
patients and 7.6% for cardiac non coronary artery disease patients
(CNCD). The diagnostic accuracy of hs-TnT value at the presenta-
tion was  quantiﬁed by an AUC of 0.89; the diagnostic accuracy of
absolute ı (AUC = 0.89) was  higher than for relative ı (AUC = 0.66)
(p < 0.001). The best value of AUC was obtained combining the
hs-TnT concentration at presentation with the absolute ı change
(AUC = 0.94). The algorithm created by the authors included the
following data: ST-segment elevation, hs-TnT at presentation, and
absolute ı change in the ﬁrst hour. A value of 28 ng/L, compared to
a value of 14 ng/L, at presentation to the ED, best separated patients
with AMI  from patients with CNCD; instead, the best discriminatory
absolute ı change was 5 ng/L [29].
All these studies indicate that the approach of absolute ı is
useful, but also characterized by several limitations and unsolved
matters: ﬁrst, each individual cTn assay will require a speciﬁc ı
determination for both absolute and relative percentage changes,
because this modiﬁcation can be inﬂuenced by analytical and
biological variability of each assay; second, the determination
of the optimal ı is dependent on the distribution of presenting
syndromes in the population studied; third, ı values should be
determined for each different time window (0–3 h, 3–6 h, and
0–6 h) [30] (Table 3). Furthermore, the superiority of absolute ı
in some studies, appears to rely principally on the fact that patients
present late after the onset of symptoms and have higher values at
baseline [14].
As a matter of fact, guidelines of the European Society of Car-
diology and recommendations of the study group on biomarkers
of the same society [13,14] recommend to use a percent ı ≥ 50%
at 3 h in patients with an initial hs-Tn value below or close to the
99th percentile and a percent ı ≥ 20% at 3 h in patients with an hs-
Tn value at admission above the 99th percentile. This approach has
been considered the best in the light of the current evidence, but, as
shown by several studies that we  have reported above, more stud-
ies are required before these recommendations can be considered
deﬁnitive.
Table 3
Absolute delta.
ı SE SP NPV PPV
Mueller et al., 2012 [27] 9.2 ng/L 89.7% 74.8% 96.5% 48.7%
Reichilin et al., 2011 [28] 7 ng/L 89% 93% 98% 64%
SE, sensitivity; SP, speciﬁcity; NPV, negative predictive value; PPV, positive predic-
tive value.
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he “age approach”
Decision limits for cTn assays are derived from normal popu-
ations, without heart disease and relatively young; in the case of
s-TnT the value of 14 ng/L is derived from a reference population
f apparently healthy subjects aged between 20 and 70 [31–33].
his is quite different from the ED population, often characterized
y older subjects with comorbidities, and leads to potential bias
n particular in the elderly [34]. As a matter of a fact, elevated
evels of hs-TnT were found in up to 22% of healthy subjects liv-
ng in community who were more than 70 years old [35,36]. A
ulti-center study conduct by Reiter et al. included 406 patients,
resenting to the ED with symptoms suggestive of AMI, who were
70 years old and reported some important ﬁndings: among elderly
atients with a ﬁnal diagnosis other than AMI, the percentage
f patients with a baseline level of hs-Tn above the 99th per-
entile was high (from 13% to 51% with different high sensitivity
ssays); the best cutoff values to separate AMIs from non-AMIs,
alculated with the ROC curves, varied substantially: the diagnos-
ic performance of hs-TnT assays at the 99th percentile (14 ng/L)
as characterized by a SE of 98% and a SP of 49% in elderly sub-
ects; on the contrary, in younger patients, SE was 88% and SP
as 86%. In the elderly, the best cutoff value was  54 ng/L, nearly
our times the 99th percentile (SE 79%, SP 96%, p < 0.001), while,
n younger patients the best cutoff value was 17 ng/L, very close
o the 99th percentile (SE 88% p = 1, SP 90% p = 0.215) [37]. More
ecently, other studies try to ﬁnd the best way to use hs-Tn in
his speciﬁc population. Olivieri et al. highlighted the concept that
he 99th percentile value of cTnT is derived from a healthy sam-
le of middle-aged adults, that, in every study, is considered the
reference popoulation”. They conﬁrmed that the percentage of
ealthy subjects with hs-TnT higher than 14 ng/L increases with
dvancing age, also considering that the older participants were
elected among those in good health status using history, clini-
al and instrumental examinations in order to avoid the presence
f conditions known to signiﬁcantly inﬂuence cTn levels, such as
HF, respiratory disease and renal failure. Moreover, a higher diag-
ostic efﬁciency [(SE + SP)/2] was obtained with an hs-TnT level of
6.8 ng/L: applying this cutoff, the percentage of false positive, in
he reference population aged more than 75 years old, was reduced
y about 90% [38]. More recently, Normann et al. studied a popula-
ion of 848 patients presenting to ED because of acute symptoms,
onsidering as an exclusion criterion the presence of a STEMI and
ividing the population into two groups: subjects aged <75 and >75
ears old. In the entire study population, an hs-TnT value >99th
ercentile was more prevalent among patients ≥75 years if com-
ared with <75 years (89.1% vs 73.3%, p < 0.001); among younger
atients the elevation was due to ACS, in particular NSTEMI, among
lderly patients non-ACS-conditions were more frequent. For the
iagnosis of NSTEMI, using a 99th percentile cutoff of 14 ng/L, the
UC was signiﬁcantly higher in younger patients than in elderly,
oth in the NSTE-ACS group (0.81 vs 0.63, p < 0.0001) and in the
hole population (0.63 vs 0.54, p < 0.0001). Similarly, the ROC-
ptimized cutoff had a better diagnostic performance in younger
han in elderly patients, both in the NSTE-ACS group (0.87 vs 0.79,
 < 0.0001) and in the whole population (0.74 vs 0.73, p < 0.0001).
he ROC optimized cutoff value for diagnosis of NSTEMI in elderly
ubjects, in NSTE-ACS group, was almost 2 fold higher than the
9th percentile cutoff (32.9 ng/L vs 14 ng/L) with a great improve-
ent in SP (78.5% vs 24.6%) but, in agreement with previous studies,
ith a decrease in SE (72.6% vs 98%) [39]. These data conﬁrm the
eed to re-think the use of hs-Tn in the elderly population, in
hich the causes of an increase in the biomarker are more fre-
uent and numerous than in a healthy young population, showing
hat a new cutoff with a better diagnostic efﬁciency must be eval-
ated.iology 62 (2013) 205–209
Not ischemic causes of hs-Tn elevation: true or false
positive?
As already mentioned, the use of hs-Tn in clinical practice allows
detection of minor damage to the heart muscle, increasing the
number of patients identiﬁed with elevated cTn concentrations but
without ACS, called false positives [17].
Therefore, on one hand, the elevation of the biomarker in non-
ischemic cardiac conditions represents an obstacle to a correct and
quick diagnosis, and may  lead to a misclassiﬁcation of patients;
on the other hand, several studies conﬁrmed that an increase in
cTn concentrations is associated with a higher risk for the subjects,
underlining the possible prognostic role of the biomarker, even in
the absence of ACS. In particular, Omland et al. studied patients
with stable CAD, ﬁnding an association between the elevation of
hs-TnT and the incidence of cardiovascular death and CHF [40];
moreover, the value of hs-TnT was also associated with the extent of
coronary atherosclerosis in subjects with CAD [41,42]. Several stud-
ies, about the prognostic role of hs-Tn in patients with CHF, have
been reported in the literature [43,44]; in particular, Latini et al.
reported an association between elevated concentrations of cTn
and adverse cardiovascular outcomes [45]. Moreover, some stud-
ies suggest that, in patients with heart failure, even in the absence
of ACS, the elevation of hs-TnT levels is useful for the evaluation of
heart failure severity, reﬂecting cardiac dysfunction evaluated by
echocardiography and natriuretic peptides [46].
All this evidence supports the assumption that the elevation
in cTn, measured with hs-assays, also has an important progno-
stic role and that patients with increased concentrations of the
biomarker require close monitoring and management, even in
the absence of ACS. It is therefore advisable that these patients,
although not affected by ACS, should be hospitalized or referred to
speciﬁc programs of control and care.
Conclusions
Hs-Tn represents an opportunity to improve the management
of patients with ACS. However, to use this biomarker at its best, the
characteristics of all hs-Tn assays should be studied, evaluated, and
known by physicians. In particular, considering the high number
of false-positive diagnoses occurring with hs-Tn, new strategies
should be investigated to improve diagnostic speciﬁcity, without
losing the beneﬁts gained in terms of sensitivity.
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